Related references
Note: Only part of the references are listed.Liver iron concentration is an independent risk factor for the prediabetic state in β-thalassemia patients
Mehrnoush Kosaryan et al.
INTERNATIONAL JOURNAL OF DIABETES IN DEVELOPING COUNTRIES (2020)
A randomized controlled trial evaluating the effects of amlodipine on myocardial iron deposition in pediatric patients with thalassemia major
Arwa Khaled et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2019)
Effective method of evaluating myocardial iron concentration in pediatric patients with thalassemia major
Arwa Khaled et al.
JOURNAL OF BLOOD MEDICINE (2019)
Combined iron chelator and T-type calcium channel blocker exerts greater efficacy on cardioprotection than monotherapy in iron-overload thalassemic mice
Sirinart Kumfu et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2018)
A randomized, controlled study evaluating effects of amlodipine addition to chelators to reduce iron loading in patients with thalassemia major
Aziz Eghbali et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2017)
A randomized trial of amlodipine in addition to standard chelation therapy in patients with thalassemia major
Juliano L. Fernandes et al.
BLOOD (2016)
Prevalence and distribution of iron overload in patients with transfusion-dependent anemias differs across geographic regions: results from the CORDELIA study
Yesim Aydinok et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2015)
Cardiomyopathy Associated with Iron Overload: How Does Iron Enter Myocytes and What are the Implications for Pharmacological Therapy?
Karn Wijarnpreecha et al.
HEMOGLOBIN (2015)
Sustained improvements in myocardial T2*over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine
Dudley J. Pennell et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Effect of L-type calcium channel blocker (amlodipine) on myocardial iron deposition in patients with thalassaemia with moderate-to-severe myocardial iron deposition: protocol for a randomised, controlled trial
Amarah Shakoor et al.
BMJ OPEN (2014)
Amlodipine Reduces Cardiac Iron Overload in Patients with Thalassemia Major: A Pilot Trial
Juliano Lara Fernandes et al.
AMERICAN JOURNAL OF MEDICINE (2013)
The Association between the Levels of Serum Ferritin and Sex Hormones in a Large Scale of Chinese Male Population
Zhenfang Liu et al.
PLOS ONE (2013)
High serum ferritin levels are associated with metabolic risk factors in non-obese Korean young adults: Korean National Health and Nutrition Examination Survey (KNHANES) IV
Ki-Dong Yoo et al.
CLINICAL ENDOCRINOLOGY (2012)
The serum hepcidin:ferritin ratio is a potential biomarker for cirrhosis
Terrence C. H. Tan et al.
LIVER INTERNATIONAL (2012)
Complications of thalassemia major and their treatment
Caterina Borgna-Pignatti et al.
EXPERT REVIEW OF HEMATOLOGY (2011)
Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities
George J. Kontoghiorghes
EXPERT OPINION ON DRUG SAFETY (2010)
Iron metabolism and infection
Colin Ratledge
FOOD AND NUTRITION BULLETIN (2007)
Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis
DJ Pennell et al.
BLOOD (2006)
Role of L-type Ca2+ channels in iron transport and iron-overload cardiomyopathy
Gavin Y. Oudit et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2006)
Transdermal androgen therapy to augment EPO in the treatment of anemia of chronic renal disease
AT Brockenbrough et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2006)
Monitoring and treatment of iron overload: State of the art and new approaches
JB Porter
SEMINARS IN HEMATOLOGY (2005)
L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy
GY Oudit et al.
NATURE MEDICINE (2003)
Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload
LJ Anderson et al.
EUROPEAN HEART JOURNAL (2001)